Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Betting On A Brexit Transition Period Is A Gamble: EMA Warning For Industry

Executive Summary

A senior official at the European Medicines Agency has warned pharmaceutical companies are taking a risk by endlessly waiting to get news on whether there would be a Brexit transition period. Drug makers still waiting to prepare for changes that may be needed once the UK leaves the EU were told 'this is your risk and your decision.'

Advertisement

Related Content

Brexit: How Do Pharma Firms Plan For An Unknown Scenario?
Change And More Change: That’s What Brexit Means For Drug Companies
EU Network Alerts Drug Companies To Legal Repercussions Of Brexit

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS121740

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel